Last reviewed · How we verify
PPV-23
At a glance
| Generic name | PPV-23 |
|---|---|
| Also known as | polysaccharide pneumococcal vaccine |
| Sponsor | Westat |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy (PHASE2)
- Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma (PHASE4)
- Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE2)
- PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (EARLY_PHASE1)
- A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above) (PHASE1)
- A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) (PHASE2, PHASE3)
- Clinical Trial of Recombinant Pneumococcal Protein Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PPV-23 CI brief — competitive landscape report
- PPV-23 updates RSS · CI watch RSS
- Westat portfolio CI